AI products go vertical
OpenAI launched GPT‑Rosalind, positioned for life‑sciences research, while reports say Codex is being expanded and embedded deeper into developer workflows — both moves point to product specialisation by workflow. Advertisers are already reassessing where ChatGPT and conversational ads fit into marketing funnels as these products become more specialised. (thenextweb.com) (startuphub.ai) (adage.com)
OpenAI is turning its products into job-specific tools, starting with a new life-sciences model and a deeper push into coding workflows. (openai.com) On April 16, OpenAI introduced GPT‑Rosalind, a limited-access model for biology, drug discovery, and translational medicine. The company said the model is tuned for chemistry, protein engineering, genomics, and multi-step scientific workflows. (openai.com) Drug discovery is the process of finding a biological target, testing compounds against it, and moving the best candidates toward human trials. OpenAI said that path still takes about 10 to 15 years in the United States, which is why it is pitching Rosalind as a tool for earlier-stage research rather than a shortcut to approved medicines. (openai.com) OpenAI is making a similar bet in software. Its Codex product page now describes Codex as an “AI coding partner” for planning, refactors, reviews, and releases, while the company’s macOS Codex app is built around multiple agents, parallel worktrees, and long-running tasks. (openai.com 1) (openai.com 2) The new pattern is less “one chatbot for everything” and more software built around a workday. OpenAI’s developers site says Codex can automate refactoring, testing, migrations, and setup tasks, while Rosalind is aimed at bioinformaticians, computational biologists, and early-discovery teams. (developers.openai.com) (help.openai.com) That specialization is arriving as OpenAI builds a business around ChatGPT beyond subscriptions. OpenAI said on March 26 that its U.S. ads pilot, launched February 9 for logged-in adult users on Free and Go plans, is meant to fund broader access while keeping ads separate from answers and clearly labeled. (openai.com) Advertisers are still working out what those placements are for. Ad Age reported last month that brands and agencies are treating ChatGPT less like a standard display channel and more like an early test bed for “agentic commerce,” while OpenAI is pitching the pilot as a way to learn how conversational ads perform. (adage.com) The ad business is moving quickly even with that uncertainty. CNBC reported on March 26 that OpenAI’s ads pilot topped $100 million in annual recurring revenue in under two months, and eMarketer reported that some advertisers still have doubts about measurement and the format’s role in the funnel. (cnbc.com) (emarketer.com) OpenAI’s own release page now lists “Codex for (almost) everything” one day before GPT‑Rosalind’s debut. The sequence shows where the company is putting product effort in April 2026: tools that fit a lab bench, a codebase, and a commercial slot inside ChatGPT. (openai.com)
